Veno-occlusive disease after an anti-CD33 therapy (gemtuzumab ozogamicin).
Bastie
J N
JN
Suzan
F
F
Garcia
I
I
Isnard
F
F
de Revel
T
T
Terre
C
C
Mayeur
D
D
Abraham
C
C
Lavielle
R
R
Castaigne
S
S
D000328:Adult; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D000079982:Gemtuzumab; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D008297:Male; D008875:Middle Aged
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000079982:Gemtuzumab